Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Can Gilead And Merck Capitalize On AstraZeneca/Daiichi Sankyo’s TROP2 Safety Concerns?

Dato-DXd’s Lung Adverse Events Could Scupper NSCLC Goals

Executive Summary

AstraZeneca and Daiichi-Sankyo’s second collaboration has taken a knock after a mixed readout from the TROPION-Lung01 study of their antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), and its rivals will hope their differently engineered ADCs can win out in the long-term.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts